<DOC>
	<DOCNO>NCT02004769</DOCNO>
	<brief_summary>Patients inoperable , locally advanced recurrent and/or HER2-positive metastatic gastric gastro-esophageal junction cancer , prior treatment metastatic disease recruit study . In current study , efficacy safety Trastuzumab combination Capecitabine/Docetaxel evaluate Chinese patient HER2 positive advance recurrent gastric cancer.60 patient could provide adequate precision rather control type I &amp; II error . Assuming target PFS 6.7m , 60 patient give 90 % CI ( 5.5 , 8.4 ) . Considering 5 % drop rate , 65 patient enrol .</brief_summary>
	<brief_title>Trastuzumab Plus Docetaxel Capecitabine For First Line Treatment Her2-Positive Advanced Gastric Cancer</brief_title>
	<detailed_description>This phase II , multi-center , open label , single arm , interventional study . Patients HER2-positive metastatic gastric gastro-esophageal junction adenocarcinoma receive prior treatment metastatic disease treat trastuzumab ( 8 mg/kg load dose follow 6 mg/kg every 3 week ) , Capecitabine ( 2000mg/m2d , d1-14 , every 3 week ) Docetaxel ( 60mg/m2 every 3 week 6 cycle ) .All patient continue receive trastuzumab Capecitabine either disease progression , occurrence unacceptable toxicity withdrawal study another reason.Primary endpoint PFS secondary endpoint ORR , OS Safety.Recruitment period:24 month ; PFS follow-up period : 80 % PFS event ; OS follow-up period : 18 month 80 % OS event , whichever occur first .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Male female . Age : 1875 year . 2 . Histologically confirm adenocarcinoma stomach gastroesophageal junction inoperable locally advanced recurrent and/or metastatic disease , amenable curative therapy . 3 . Measurable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 , assess use image technique ( CT MRI ) . 4 . HER2 positive tumor ( primary tumor metastasis , HER2 positive define IHC2+ confirmatory FISH+ result ( HER2 : CEP17 ratio ≥2 ) , IHC 3+ result ) assess central laboratory . Accurate validate assay method use . 5 . ECOG Performance status 01 . 6 . Life expectancy least 3 month . 7 . Signed informed consent . 8 . Previous chemotherapy advanced/metastatic disease ( prior adjuvant/neoadjuvant therapy allow least 6 month elapse completion adjuvant/neoadjuvant therapy enrollment study ; adjuvant/neoadjuvant therapy docetaxel allow ) . 9 .Lack physical integrity upper gastrointestinal tract malabsorption syndrome ( e.g . patient partial total gastrectomy enter study , jejunostomy probe ) . 10 . Patients active ( significant uncontrolled ) gastrointestinal bleeding . 11 . Residual relevant toxicity result previous therapy ( exception alopecia ) , e.g . neurologic toxicity ≥ grade 2 NCICTCAE version 4.0 . 12 . Other malignancy within last 5 year , except carcinoma situ cervix , basal cell carcinoma . 13 . Hematologic , Biochemical Organ Function 14 . Neutrophil count &lt; 1.5 × 109/L , platelet count &lt; 100 × 109/L . 15 . Serum bilirubin &gt; 1.5 × upper limit normal ( ULN ) ; , AST ALT &gt; 2.5 × ULN ( &gt; 5 × ULN patient liver metastasis ) ; , alkaline phosphatase &gt; 2.5 × ULN ( &gt; 5 × ULN patient liver metastasis , &gt; 10 × ULN patient bone liver metastasis ) ; albumin &lt; 25 g/L . 16 . Creatinine clearance &lt; 60 mL/min . 1 . History document congestive heart failure ; angina pectoris require medication ; evidence transmural myocardial infarction ECG ; poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) ; clinically significant valvular heart disease ; high risk uncontrollable arrhythmia . 2 . Baseline LVEF &lt; 50 % ( measure echocardiography MUGA ) . 3 . Patients dyspnea rest due complication advance malignancy disease , require supportive oxygen therapy . 4 . Patients receive chronic high dose corticosteroid therapy . ( Inhaled steroid short course oral steroid antiemesis appetite stimulant allow ) . 5 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . 6 . History clinical evidence brain metastasis . 7 . Serious uncontrolled systemic intercurrent illness , e.g . infection poorly control diabetes . 8 . Positive serum pregnancy test woman childbearing potential . 9 . Subjects reproductive potential willing use effective method contraception . 10 . Received investigational drug treatment within 4 week start study treatment . 11 . Radiotherapy within 4 week start study treatment ( 2 week interval allow palliative radiotherapy give bone metastatic site peripherally patient recover acute toxicity ) . 12 . Major surgery within 4 week start study treatment , without complete recovery . 13 . Patients know active infection HIV , HBV , HCV . 14 . Known hypersensitivity study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metastatic gastric gastro-esophageal junction cancer</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>First-line therapy</keyword>
</DOC>